December 19, 2012
Former Pfizer Animal Health executive Paul Hays was named president Monday of Virbac Corp.’s U.S. commercial operations.
Hays will oversee sales, marketing, communications and technical services as well as brand management, customer relations and business planning.
Fort Worth, Texas-based Virbac Animal Health manufactures an array of pharmaceutical products for cats, dogs, equine and farm animals, including the heartworm preventive Iverhart, the dermatological shampoo Dermazole and the antibiotic Biomox.
Many Virbac products are sold exclusively through veterinarians.
Hays worked as vice president of global diagnostics at Pfizer Animal Health since 2011, after his previous employer, Synbiotics Corp., where he served as CEO and president, was purchased by Pfizer.
Before joining Synbiotics, Hays was an executive at Boehringer Ingelheim Vetmedica Inc., where he last served as executive vice president of U.S. business operations.
Hays will report to Erik Martinez, CEO of Virbac North America.
“Paul is a seasoned executive and a proven strategic leader with vast experience in managing pharmaceutical businesses, serving both U.S. and global customers and bringing products to market,” Martinez said. “Along with his animal health experience, this makes Paul the perfect leader to reinforce Virbac’s passion for animals and continue Virbac’s legacy of supporting both our veterinarian customers and pet owners.”
Source URL: https://www.veterinarypracticenews.com/virbac-chooses-paul-hays-to-head-u-s-commercial-operations/
Copyright ©2019 Veterinary Practice News unless otherwise noted.